Even under the best of circumstances, remembering to take a daily pill can be a challenge. For someone living with ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

In patients with frequent severe hypoglycaemic events, allogeneic pancreatic islet transplantation results in better glycaemic control than insulin therapy alone, enhances quality of life, and reduces ...

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.

An eight-year-old boy in Ahmedabad, initially diagnosed with Type 1 diabetes, was eventually found to have Maturity-Onset Diabetes of the Young (MODY) after genetic testing. His condition improved ...

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...

A settlement with drug-maker Novo Nordisk resolves the state's years-long litigation over insulin pricing and follows similar settlements already reached with Eli Lilly and Sanofi. “In 2018 ...